Accelerating Medicines Partnership® Program - Alzheimer's Disease 1.0
Revolutionizing knowledge of Alzheimer’s disease
The Accelerating Medicines Partnership® (AMP®) Program Alzheimer’s disease (AMP AD) was the first stage of a precompetitive partnership among government, industry and nonprofit organizations that focused on discovering novel, clinically relevant therapeutic targets, and on developing biomarkers to help validate existing therapeutic targets for Alzheimer’s disease.
This multisector partnership, managed by the Foundation for the NIH from 2014-2022, focused on providing a data-driven approach for identification and validation of biomarkers and disease-relevant targets that will lead to increased clinical trial success.
About Alzheimer’s Disease
Alzheimer's disease is projected to affect approximately 14 million people by the year 2060. Alzheimer’s is a progressive brain disorder that is the most common cause of dementia in older adults. Dementia is the loss of thinking, remembering, and reasoning abilities (neuro cognitive functions) to the extent that it interferes with a person’s daily life and activities. It is not a normal part of aging and has many potential causes. Alzheimer’s disease is characterized by changes in the brain called amyloid plaques and tau tangles as well as a loss of connections between nerve cells (neurons) in the brain. Neurons transmit messages between different parts of the brain, and from the brain to muscles and organs in the body. AMP AD worked to further unravel the complex molecular changes involved in Alzheimer’s disease to speed up the identification of novel drug targets. For more information on Alzheimer’s disease and related dementias click here.
Need for New Therapies
There has been a high failure rate of Alzheimer’s disease drug candidates in end stage clinical trials due to lack of efficacy or unforeseen toxicity that demonstrates the continued need for a deeper understanding of disease complexity and a data-driven approach for identification and validation of disease-relevant targets.
The success of clinical trials aimed at developing new treatments for Alzheimer’s disease hinges on developing a deeper mechanistic understanding of disease drivers. AMP AD contributed to this effort through two projects:
- Biomarkers Project – explored the utility of tau imaging and novel fluid biomarkers for tracking responsiveness to treatment and/or disease progression.
- Target Discovery and Preclinical Validation Project – integrated and shared analysis of large-scale molecular data from human brain samples with network modeling approaches and experimental validation to rapidly identify novel, clinically relevant therapeutic targets. Target discovery efforts for Alzheimer’s disease continue through the AMP AD 2.0 project.
Read more about AMP AD on the National Institute on Aging’s website.
AMP AD Knowledge Portal
Click here to discover and download Alzheimer's disease data, analyses, and tools from AMP AD.
AMP AD Agora Platform
Agora is an open-source platform, created to provide curated AMP AD verified systems biology analyses showing which genes are associated with Alzheimer's disease (AD). Click here to learn more.
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- U.S. Food and Drug Administration (FDA)
- AbbVie Inc.*
- Alliance for Aging Research*
- Alzheimer's Association®*
- Alzheimer’s Drug Discovery Foundation*
- Biogen Inc.*
- Eli Lilly and Company*
- The Geoffrey Beene Foundation Alzheimer's Initiative*
- Vradenburg Foundation*
*Provided financial and/or in-kind support for this project.
Results & Accomplishments
The first stage of AMP AD delivered multi-omic data and analytical resources, mechanistic insights, and a systems-based data-driven process for target discovery and validation. The project’s accomplishments include:
- Generating rich, human, multi-omic data, which has been made available to >3000 users to date (60% academia / 40% industry).
- Establishing new mechanistic disease insights on role of the genome, proteome, metabolome and microbiome.
- Increasing the availability of molecular network models of disease pathways.
- Phenotyping animal models and evaluating them relative to human molecular networks.
- Identifying 542 unique targets and making them available through the Agora Platform, along with supporting evidence and extensive druggability information.
- Completing experimental validation for over 20 candidate targets.
Over 200 publications based on AMP AD datasets, to explore publications click here. Recent:
Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases – Scientific Data
A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research – Scientific Data
The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease – Scientific Data
Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease – Scientific Data
Generation and quality control of lipidomics data for the Alzheimer’s disease neuroimaging initiative cohort – Scientific Data
Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts – Scientific Data
- NIA Press Release (October 1, 2019): NIH-funded translational research centers to speed, diversify Alzheimer's drug discovery
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.